WO2008119717A1 - Composés présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine - Google Patents
Composés présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine Download PDFInfo
- Publication number
- WO2008119717A1 WO2008119717A1 PCT/EP2008/053596 EP2008053596W WO2008119717A1 WO 2008119717 A1 WO2008119717 A1 WO 2008119717A1 EP 2008053596 W EP2008053596 W EP 2008053596W WO 2008119717 A1 WO2008119717 A1 WO 2008119717A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- disorder
- compounds
- formula
- Prior art date
Links
- 0 Cc1c(*)cc(*)c(NC(NC2CC(*C3CCC(CO*)CC3)NCC2)=O)c1* Chemical compound Cc1c(*)cc(*)c(NC(NC2CC(*C3CCC(CO*)CC3)NCC2)=O)c1* 0.000 description 3
- OMJVURYULJESQX-UHFFFAOYSA-N Cc(cc1)cc(N2C(CC3)CCN3C3CCC(COC)CC3)c1NC2=O Chemical compound Cc(cc1)cc(N2C(CC3)CCN3C3CCC(COC)CC3)c1NC2=O OMJVURYULJESQX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- M 1 receptor agonists have been sought for the symptomatic treatment of cognitive decline. More recently, a number of groups have shown that muscarinic receptor agonists display an atypical antipsychotic-like profile in a range of pre-clinical paradigms.
- the muscarinic agonist, xanomeline reverses a number of dopamine driven behaviours, including amphetamine induced locomotion in rats, apomorphine induced climbing in mice, dopamine agonist driven turning in unilateral 6-OH-DA lesioned rats and amphetamine-induced motor unrest in monkeys (without EPS liability).
- alkyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms.
- C 1-6 alkyl means a straight or branched alkyl containing at least 1 , and at most 6, carbon atoms. means a straight or branched alkyl containing at least 1 , and at most 4, carbon atoms.
- C 1-2 alkyl means a straight or branched alkyl containing at least 1 , and at most
- R 5 is selected from hydrogen, chloro, bromo, fluoro, methyl, ethyl, methoxy and trifluoromethyl.
- salts of formula (I) should be pharmaceutically acceptable.
- Suitable salts will be apparent to those skilled in the art and include for example mono- or di- basic salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric, sulfamic phosphoric, hydroiodic, phosphoric or metaphosphoric acid; and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, (1 R)-(-)-10-camphorsulphonic, (1S)-(+)-10- camphorsulphonic, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (
- Possible prodrugs for some compounds of the invention include : esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.
- Each dosage unit for oral administration contains, for example, from 1 to 250 mg (and for parenteral administration contains, for example, from 0.1 to 25 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
- the example compounds below were tested in both of the above assays, and were each found to have an average pEC 50 value of > 6.0 at the muscarinic M 1 receptor, and intrinsic activity of greater than or equal to 0.3.
- FLIPR experiments on M 2-5 receptor to determine receptor subtype selectivity To determine selectivity of compounds of the invention against other muscarinic receptor subtypes, compounds were characterized in FLIPR experiments in CHO cells with stable expression of human muscarinic receptors, M 2 , M 3 , M 4 or M 5 . In the case of M 2 and M 4 receptors, chimeric G-protein Gqi5 was also co-expressed to couple receptors to the calcium signaling pathway.
Abstract
L'invention concerne des composés représentés par la formule (I), ou un sel de ces derniers. Dans ladite formule, R4, R5, R6, Q et R1 sont tels que définis dans la description. L'invention concerne également des utilisations des composés en tant que médicaments ainsi que dans la préparation de médicaments destinés au traitement de troubles psychotiques et de troubles cognitifs. L'invention concerne en outre des compositions pharmaceutiques comprenant lesdits composés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0706187.2A GB0706187D0 (en) | 2007-03-29 | 2007-03-29 | Compounds |
GB0706187.2 | 2007-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008119717A1 true WO2008119717A1 (fr) | 2008-10-09 |
Family
ID=38050503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/053596 WO2008119717A1 (fr) | 2007-03-29 | 2008-03-27 | Composés présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0706187D0 (fr) |
WO (1) | WO2008119717A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8283364B2 (en) | 2005-09-30 | 2012-10-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8288412B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8288413B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
US8344000B2 (en) | 2007-09-20 | 2013-01-01 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
CN115745765A (zh) * | 2022-11-22 | 2023-03-07 | 浙大宁波理工学院 | 一种对溴烷基环己酮类化合物的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996013262A1 (fr) * | 1994-10-27 | 1996-05-09 | Merck & Co., Inc. | Antagonistes de muscarine |
WO1997016186A1 (fr) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Agonistes de la muscarine |
EP1221443A1 (fr) * | 1999-10-13 | 2002-07-10 | Banyu Pharmaceutical Co., Ltd. | Derives d'imidazolidinone a substitution |
WO2003105781A2 (fr) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Compositions ophtalmiques destinees a traiter l'hypertension oculaire |
WO2007107565A1 (fr) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine |
WO2007107567A1 (fr) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine |
WO2007107566A1 (fr) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine |
-
2007
- 2007-03-29 GB GBGB0706187.2A patent/GB0706187D0/en not_active Ceased
-
2008
- 2008-03-27 WO PCT/EP2008/053596 patent/WO2008119717A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996013262A1 (fr) * | 1994-10-27 | 1996-05-09 | Merck & Co., Inc. | Antagonistes de muscarine |
WO1997016186A1 (fr) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Agonistes de la muscarine |
EP1221443A1 (fr) * | 1999-10-13 | 2002-07-10 | Banyu Pharmaceutical Co., Ltd. | Derives d'imidazolidinone a substitution |
WO2003105781A2 (fr) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Compositions ophtalmiques destinees a traiter l'hypertension oculaire |
WO2007107565A1 (fr) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine |
WO2007107567A1 (fr) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine |
WO2007107566A1 (fr) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8283364B2 (en) | 2005-09-30 | 2012-10-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8288412B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8288413B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
US8481566B2 (en) | 2005-09-30 | 2013-07-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8344000B2 (en) | 2007-09-20 | 2013-01-01 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
CN115745765A (zh) * | 2022-11-22 | 2023-03-07 | 浙大宁波理工学院 | 一种对溴烷基环己酮类化合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
GB0706187D0 (en) | 2007-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8481566B2 (en) | Compounds which have activity at M1 receptor and their uses in medicine | |
EP1960389B1 (fr) | Composes exerçant une activite au niveau du recepteur m1 et leurs utilisations en medecine | |
US8299257B2 (en) | Compounds which have activity at M1receptor and their uses in medicine | |
US20080306112A1 (en) | Benzimidazolones Which Have Activity at M1 Receptor | |
EP1996188B1 (fr) | Benzimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine | |
EP1996189B1 (fr) | Benzimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine | |
WO2008119720A1 (fr) | Dérivés de 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one qui ont une activité sur le récepteur m1 et leur utilisation en médecine | |
WO2008119716A1 (fr) | Dérivés de 1- (1-cyclohexyl-4-pipéridinyl) -1, 3-dihydro-2h-benzimidazol-2-one présentant une activité sur le récepteur m1 et leur utilisation en médecine | |
WO2008119718A1 (fr) | Composés qui ont une activité au niveau du récepteur m1 et leurs utilisations en médecine | |
WO2008119713A1 (fr) | Dérivés de 1- (1-cyclohexyl-4-pipéridinyl) -1, 3-dihydro-2h-benzimidazol-2-one présentant une activité sur le récepteur m1 et leur utilisation en médecine | |
WO2008119717A1 (fr) | Composés présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine | |
WO2008119715A1 (fr) | Dérivés de 1- (1-cyclohexyl-4-pipéridinyl) -1, 3-dihydro-2h-benzimidazol-2-one présentant une activité sur le récepteur m1 et leur utilisation en médecine | |
WO2008119712A1 (fr) | Dérivés de benzoimidazoles présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine | |
WO2008119721A1 (fr) | Composés présentant une activité sur le récepteur m1 et utilisations de ceux-ci en médecine | |
WO2008119711A1 (fr) | Composés de benzimidazolone substitués qui ont une activité au niveau du récepteur m1 et leurs utilisations en médecine | |
WO2008119719A1 (fr) | Dérivés de 1-(1-cyclohexyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one qui ont une activité sur le récepteur m1 et leur utilisation en médecine | |
WO2008119714A1 (fr) | Composés qui ont une activité au niveau du récepteur m1 et leurs utilisations en médecine | |
EP2344483B1 (fr) | Composés qui ont une activité au niveau du récepteur m1 et leurs utilisations en médecine | |
EP2197441A1 (fr) | Composés ayant une activité au niveau du récepteur m1 et utilisations de ces derniers en médecine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08718251 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08718251 Country of ref document: EP Kind code of ref document: A1 |